Walter M. Stadler to Biomarkers, Tumor
This is a "connection" page, showing publications Walter M. Stadler has written about Biomarkers, Tumor.
Connection Strength
1.083
-
Fuzzy thinking on biomarkers. Urol Oncol. 2007 Mar-Apr; 25(2):97-100.
Score: 0.158
-
Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing? J Clin Oncol. 2005 Nov 01; 23(31):8124-5; author reply 8125-6.
Score: 0.144
-
New trial designs to assess antitumor and antiproliferative agents in prostate cancer. Invest New Drugs. 2002 May; 20(2):201-8.
Score: 0.113
-
Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. Cancer. 2018 07 15; 124(14):3052-3065.
Score: 0.086
-
Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013 Dec 15; 19(24):6891-901.
Score: 0.063
-
Predictive markers in advanced renal cell carcinoma. Semin Oncol. 2013 Aug; 40(4):459-64.
Score: 0.062
-
A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int. 2011 Sep; 108(5):679-86.
Score: 0.051
-
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res. 2010 Mar 15; 16(6):1745-55.
Score: 0.049
-
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8.
Score: 0.044
-
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol. 2008 Aug 01; 26(22):3743-8.
Score: 0.044
-
A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res. 2004 May 15; 10(10):3365-70.
Score: 0.033
-
A phase II trial of oral temozolomide in patients with metastatic renal cell cancer. Cancer Chemother Pharmacol. 2002 Aug; 50(2):160-2.
Score: 0.029
-
NF2-mutated Renal Carcinomas Have Common Morphologic Features Which Overlap With Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma: A Comprehensive Study of 14 Cases. Am J Surg Pathol. 2022 05 01; 46(5):617-627.
Score: 0.028
-
Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin Cancer Res. 2000 Jul; 6(7):2618-25.
Score: 0.025
-
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Future Oncol. 2019 May; 15(15):1683-1695.
Score: 0.023
-
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol. 2018 05 10; 36(14):1389-1395.
Score: 0.021
-
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018 04 01; 36(10):991-999.
Score: 0.021
-
Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol. 1996 Oct; 156(4):1280-5.
Score: 0.019
-
Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol. 1996 Aug; 156(2 Pt 1):363-7.
Score: 0.019
-
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016 Apr 20; 34(12):1402-18.
Score: 0.018
-
A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. Cancer. 2014 Jun 01; 120(11):1647-55.
Score: 0.016
-
Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer. Clin Genitourin Cancer. 2006 Sep; 5(2):150-4.
Score: 0.010
-
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol. 2003 Jul 15; 21(14):2673-8.
Score: 0.008